Clinical Trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study acronym: RASolve 301
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Protocol Amendment History 4 changes
notable Trial sites expanded: 143 -> 151 locations 2026-06-26
critical Primary endpoint(s) modified 2026-05-30
notable Enrollment increased: 420 -> 590 participants 2026-05-30
notable Trial sites expanded: 129 -> 143 locations 2026-05-30
Trial Details
NCT Number NCT06881784
Lead Sponsor Revolution Medicines, Inc.
Conditions NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 590 participants
Start Date 2025-05-06
Primary Completion 2027-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06